Compare BioNano Genomics Inc (BNGO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Omnicom Group Inc. — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Omnicom Group Inc. trades at $85.17 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 1726.2× BioNano Genomics Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | OMC | |
|---|---|---|
Market Cap | $13.66M | $23.58B |
Sector | Health | Media |
52-Week High | $4.92 | $86.22 |
52-Week Low | $1.06 | $67.27 |
Enterprise Value | $16.26M | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Omnicom Group (OMC) trades at $85.34, up 0.82% today, with a bullish technical signal from moving averages and a consensus price target of $107.00. Recent Q2 2026 earnings beat expectations with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company shows strong cash flow from operations at $2.94 billion in 2025 and pays a $0.80 quarterly dividend.
Outlook is positive with post-merger synergies driving margin expansion, but high P/E of 232.3 and integration risks from the Interpublic acquisition pose challenges. Analyst sentiment is mixed with 32% buy ratings, highlighting value potential amid execution concerns. Key catalysts include sustained organic growth and cost savings realization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
